BlackRock Investment Management’s Tempest Therapeutics TPST Stock Holding History

BlackRock Investment Management’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$200K	Hold	45	–	–	﹤0.01%	3231
2016 Q3	$943K	Buy	45 +1	+2%	+$18.1K	﹤0.01%	2717
2016 Q2	$672K	Buy	44 +15	+52%	+$343K	﹤0.01%	2890
2016 Q1	$797K	Buy	29 +1	+4%	+$21.1K	﹤0.01%	2635
2015 Q4	$807K	Hold	28	–	–	﹤0.01%	2744
2015 Q3	$700K	Sell	28 -1	-3%	-$67.3K	﹤0.01%	2862
2015 Q2	$2.42M	Buy	29 +10	+53%	+$916K	﹤0.01%	2077
2015 Q1	$1.97M	Buy	19 +2	+12%	+$266K	﹤0.01%	2039
2014 Q4	$2.23M	Hold	17	–	–	﹤0.01%	1957
2014 Q3	$837K	Hold	17	–	–	﹤0.01%	2645
2014 Q2	$446K	Buy	17 +6	+55%	+$141K	﹤0.01%	3097
2014 Q1	$278K	Buy	11 +3	+38%	+$85K	﹤0.01%	3181
2013 Q4	$226K	Hold	8	–	–	﹤0.01%	3204
2013 Q3	$245K	Hold	8	–	–	﹤0.01%	3149
2013 Q2	$304K	Buy	+8	New	+$301K	﹤0.01%	3083

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CQS Cayman Camana Bay, Grand Cayman, Cayman Islands $2.26B AUM 1.31% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock Investment Management's TPST Position: Q4 2016 in Review

BlackRock Investment Management held its Tempest Therapeutics (TPST) position steady in Q4 2016 at 45 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #3231.

BlackRock Investment Management first reported a position in TPST in Q2 2013 and has held it in 15 quarters since. The position peaked at $2.42M in Q2 2015. 84 funds tracked by Wall St. Rank hold TPST as of Q4 2016.

BlackRock Investment Management held 45 shares of Tempest Therapeutics worth $200K as of Q4 2016.
BlackRock Investment Management left its Tempest Therapeutics share count unchanged in Q4 2016.
Tempest Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3231 holding.
BlackRock Investment Management first reported a position in Tempest Therapeutics in Q2 2013 and has held it in 15 quarters since.
BlackRock Investment Management's Tempest Therapeutics position peaked at $2.42M in Q2 2015.
84 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.